Amorolfine

Amorolfine
Clinical data
AHFS/Drugs.com International Drug Names
ATC code D01AE16 (WHO)
Identifiers
CAS Number 78613-35-1 YesY
PubChem (CID) 54260
ChemSpider 49010 YesY
UNII AB0BHP2FH0 YesY
KEGG D02923 YesY
ChEBI CHEBI:599440 YesY
ChEMBL CHEMBL489411 YesY
Chemical and physical data
Formula C21H35NO
Molar mass 317.509 g/mol
3D model (Jmol) Interactive image
  (verify)

Amorolfine (or amorolfin), is a morpholine antifungal drug that inhibits Δ14-sterol reductase and cholestenol Δ-isomerase, which depletes ergosterol and causes ignosterol to accumulate in the fungal cytoplasmic cell membranes. Marketed as Curanail, Loceryl, Locetar, and Odenil, amorolfine is commonly available in the form of a nail lacquer, containing 5% amorolfine hydrochloride as the active ingredient. It is used to treat onychomycosis (fungal infection of the toe- and fingernails). Amorolfine 5% nail lacquer in once-weekly or twice-weekly applications has been shown in two studies to be between 60% and 71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment) were 38% and 46%. However, full experimental details of these trials were not available and since they were first reported in 1992 there have been no subsequent trials.[1]

It is a topical solution for the treatment of toenail infections. Systemic treatments may be considered more effective.[1]

It is approved for sale over-the-counter in Australia, Russia and the UK (recently re-classified to over-the-counter status), and is approved for the treatment of toenail fungus by prescription in other countries. It is not approved for the treatment of onychomycosis in the United States or Canada, but can be ordered from there by mail from other countries.[2]

Notes

  1. 1 2 Hywel C. Williams (2003). Evidence-Based Dermatology. Blackwell.
  2. It can readily be verified that Curanail is advertised on websites such as US Amazon.com, shipped from abroad.
This article is issued from Wikipedia - version of the 10/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.